Focus of hph Management


  • Pharmaceutical and Biotechnology Industry Consulting
  • Business Strategy and Marketing
  • Executive Management



Personal Profile










Hans Peter Hasler is a senior executive and top-level advisor to the life-sciences industry. He has an international track record and in-depth operational, commercial, and general management expertise. During his career, Mr. Hasler has managed the growth of leading players in the pharmaceutical industry and has successfully launched several blockbuster drugs.


Mr. Hasler has a broad network at the executive level with a high number of pharmaceutical and biotechnology corporations. He is Chairman of the Board of HBM Healthcare Investments AG in Switzerland; Director of the Board of Minerva Neuroscience Inc., Boston; Member of the Board of Shield Therapeutics plc, London; and Chief Advisor of SBTech Advisory, a small asset scouting company located in Israel, Switzerland, and the USA.


Mr. Hasler is founder and CEO of Vicarius Pharma. The company develops and executes successful European go-to-market strategies for specialty, rare/orphan, and hospital products.



Professional Experience

Global Life Sciences Advisor, Switzerland

Chief Executive Officer, Vicarius Pharma, Switzerland

Chief Operating Officer, Elan Pharmaceuticals, Ireland/Switzerland

Chief Operating Officer, Biogen, USA/Switzerland

Head of Commercial Operations, Biogen, USA

SVP, Biogen, Switzerland

Chief Marketing Officer, Wyeth, USA

Managing Director, Wyeth, Germany

General Manager, Wyeth, Switzerland/Austria/CEE



Key Achievements

Elan Pharmaceuticals

  • Sale of Tysabri (IV multiple sclerosis compound) as COO of Elan Pharmaceuticals.



  • Lead in-licensing of Tecfidera (dimethyl fumarate) with annual revenues of over 4 billion USD;
  • Transferred international headquarters from Paris to Zug, Switzerland and accelerated MS leadership position by optimizing structural and marketing efficiency;
  • Initiated and planned Biogen`s entry into the biosimilar market segment;
  • Successfully launched Tysabri globally (annual revenues of 3 billion USD) and monitored regulatory re-entry in Europe.


Wyeth (Global Headquarters)

  • Supported Wyeth as chief marketing officer and member of the global executive leadership team to achieve revenues of 10 billion USD;
  • Led the improvement of R&D/business collaborations while co-chairing eight therapeutic business units;
  • Assumed global launch/post launch responsibility for Enbrel (rheumatoid arthritis), Effexor (antidepressant), and Tazobactam (antibiotic).


Wyeth Group Germany (in charge of DACH-Region)

  • Reorganized organizational structure in Germany and led successful transformation of a generic product supplier into a state-of-the-art marketing organization;
  • Managed the successful launch of Effexor (antidepressant), Enbrel (RA) and ReFacto (Factor VIII hemophilia).






German, English, French




Board Memberships


Chairman of the Board, HBM Healthcare Investments, Switzerland

Member of the Board, Shield Therapeutics plc, London

Director of the Board, Minerva Neuroscience Inc., Boston

Chairman of the Board, Medical Imaging Analysis Center (MIAC), University Hospital Basel, Switzerland






HPH Management GmbH

Hans Peter Hasler

Bodenstrasse 23

Mail Box 255

CH-6403 Küssnacht a.R.



Phone  +41 79 403 56 02


© 2019 hph Management GmbH

Terms & Conditions

Privacy Policy

Focus of

hph Management


  • Pharmaceutical and Biotechnology Industry Consulting
  • Business Strategy and Marketing
  • Executive Management